Herbalife enters the back half of 2026 with a striking contradiction at its core: options traders turned sharply bullish this week, just days after the stock fell more than 10% on disappointing Q2 results.
The options signal is the most striking data point of the week. The put/call ratio dropped to 0.318 on August 7 — the lowest reading of the past 52 weeks, against a prior low also at 0.318 and a 52-week high of 1.17. That reading sits more than four standard deviations below the 20-day mean of 0.53, an extreme that suggests a sudden and heavy tilt toward call buying relative to puts. To frame the context: for most of the past month, the PCR tracked in a tight band between 0.52 and 0.56. The single-session collapse to 0.318 represents a sharp break from that pattern, happening precisely on the session following the earnings drop.
Short interest and borrow conditions tell a materially different story, and the contrast matters. Bears have actually been retreating, not advancing. Short interest as a percentage of the free float is running at roughly 8.8%, which is meaningful but not extreme — and has eased nearly 1% over the past week even as it has climbed around 10% over the past month. The month-over-month build suggests shorts added positions in July as the stock weakened, but the most recent week shows that momentum has stalled. Borrowing remains almost frictionless: cost to borrow is just 0.49%, and availability is ample at around 492% of short interest — meaning roughly five shares are available to borrow for every one already shorted. That is a loose lending market, nowhere near squeeze territory.
The Street took the Q2 results as a negative catalyst but stopped short of a full downgrade cycle. Citigroup, which has maintained a Buy rating, cut its price target from $21 to $17 on August 7 — a meaningful step down, but the firm held its bullish stance even with the stock trading at $12.35. The consensus mean target is $17, implying roughly 38% upside from current levels, though that number reflects only a handful of active analysts and should be read with appropriate caution. Factor scores offer limited near-term comfort: EPS momentum over 30 days ranks in the 39th percentile, a softer reading, while forward EPS growth expectations rank higher at the 68th percentile — the market still expects earnings recovery, but the path has clearly become bumpier. The short score of around 59 has been broadly stable over the past two weeks, suggesting no fresh escalation in bearish conviction from the quant side.
The institutional register is notable for its concentration. The Baupost Group holds approximately 8.8% of shares, and Route One Investment Company holds a further 7.9% — two deep-value-oriented active managers sitting on a stock that has lost roughly 6% over the past month and trades at a PE of under 4x. BlackRock added around 686,000 shares in the most recent reported period through July, a smaller but directionally constructive move. Insiders, by contrast, have been net sellers: the COO and Chief Commercial Officer together registered over $3.5 million in net sales over the past 90 days, with the most recent transaction on August 4. The divergence between institutional holders staying patient and insiders trimming is worth noting.
Earnings history offers context without comfort. The Q2 print on August 5 produced a 10% single-day decline — the only reaction data available, but it was a clean miss. The next scheduled event is not until November 4, which means the coming weeks are likely to be driven by positioning adjustments and macro sentiment rather than fundamental catalysts. The key tension to watch is whether the spike in call buying represents genuine directional conviction or a short-term recovery trade fading the post-earnings flush — and whether short interest resumes its month-long build or continues to ease from here.
See the live data behind this article on ORTEX.
Open HLF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
